DIA Biosimilars 2013

Synta Pharmaceuticals

PSI, Synta Pharmaceuticals collaborate on trial

Tuesday, March 5, 2013 04:00 PM

Switzerland-based CRO PSI said it has been selected by Synta Pharmaceuticals to conduct its GALAXY-2 trial, a randomized, phase III study of Ganetespib in combination with Docetaxel versus Docetaxel alone in patients with advanced non-small cell lung cancer.  PSI currently is initiating this 500-patient study across 15-plus countries.

More... »

Cenduit: Now with Patient Reminders

Synta releases data on ganetespib across range of malignancies

Wednesday, April 4, 2012 09:00 AM

Lexington, Mass.-based Synta Pharmaceuticals has released results on the use of ganetespib, the most advanced heat shock protein 90 (Hsp90) inhibitor in clinical development, in melanoma and colorectal cancer.

More... »

CRF Health – eCOA Forum

Synta announces phase IIb/III trial for Ganetespib

Monday, March 7, 2011 07:43 AM

Synta Pharmaceuticals, a biopharmaceutical company that develops small molecule drugs for medical conditions, announced that a phase IIb/III clinical trial of ganetespib (STA-9090) in combination with docetaxel in non-small cell lung cancer (NSCLC) will begin in 2011. Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) that is structurally unrelated to earlier Hsp90 inhibitors such as 17-AAG. 

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs